Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes |
| |
| Authors: | Thomas F Dejgaard MD Nanna B Johansen MD PhD Christian S Frandsen MD PhD Ali Asmar MD PhD Lise Tarnow MD DMSc Filip K Knop MD PhD Sten Madsbad MD DMSc Henrik U Andersen MD DMSc |
| |
| Institution: | 1. Steno Diabetes Center, University of Copenhagen, Gentofte, Denmark;2. Department of Endocrinology, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark;3. Danish Diabetes Academy, Odense, Denmark;4. Research Centre for Prevention and Health, Capital Region of Denmark, Copenhagen, Denmark;5. Department of Clinical Physiology and Nuclear Medicine, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark;6. Department of Clinical Research, Nordsj?llands Hospital Hiller?d, University of Copenhagen, Hiller?d, Denmark;7. Department of Clinical Epidemiology, Aarhus University, Aarhus, Denmark;8. Center for Diabetes Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark;9. Faculty of Health and Medical Sciences, The NNF Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark;10. Faculty of Health and Medical Sciences, Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark |
| |
| Abstract: | We investigated the short‐term effect of adding liraglutide 1.8 mg once daily to insulin treatment on cardiovascular risk factors in patients with type 1 diabetes. In total, 100 overweight (BMI ≥25 kg/m2) adult patients (age ≥18 years) with type 1 diabetes and HbA1c ≥ 8% (64 mmol/mol) were randomized to liraglutide 1.8 mg or placebo added to insulin treatment in a 24‐week double‐blinded, placebo‐controlled trial. At baseline and after 24 weeks of treatment, 24‐hour blood pressure and heart rate, pulse pressure, pulse wave velocity and carotid intima‐media thickness were evaluated. Compared with placebo, liraglutide increased 24‐hour heart rate by 4.6 beats per minute (BPM); P = .0015, daytime heart rate by 3.7; P = .0240 and night‐time heart rate by 7.5 BPM; P < .001 after 24 weeks. Diastolic nocturnal blood pressure increased by 4 mm Hg; P = .0362 in the liraglutide group compared with placebo. In conclusion, in patients with long‐standing type 1 diabetes, liraglutide as add‐on to insulin increased heart rate and did not improve other cardiovascular risk factors after 24 weeks of treatment. |
| |
| Keywords: | cardiovascular disease clinical trial
GLP‐1 analogue liraglutide type 1 diabetes |
|
|
